Sosei Group entered a discovery collaboration and licensing deal with AbbVie, initially focused on inflammatory and autoimmune diseases.
GlaxoSmithKline started a trial to test an experimental rheumatoid arthritis drug on patients suffering from COVID-19 related pneumonia.
Eli Lilly and Oxford, England-based Sitryx entered an exclusive global licensing and research collaboration. The two companies will work to develop up to four preclinical compounds discovered by Sitryx for autoimmune diseases.
Florida-based Catalyst Pharmaceuticals is attempting to show in court that the price of a newly approved treatment for a rare autoimmune disease and pressure from U.S. Sen. Bernie Sanders lead to the approval of a rival treatment.
Jeffrey Bluestone, the noted scientific researcher and pioneer in understanding T-cell activation and immune tolerance in cancer patients, stepped down from his role as chief executive of the Parker Institute for Cancer Immunotherapy to launch Sonoma Biotherapeutics.
Changes in U.S. Food and Drug Administration procedures meant to speed approvals for medications may have resulted in less exacting standards, a new analysis suggests.
AbbVie reported that the company’s drug Skyrizi met both primary and all ranked secondary endpoints in a Phase III trial that went head-to-head with Novartis’ Cosentyx in plaque psoriasis.
Shares of Durect Corporation plunged more than 31 percent after the company announced the Phase IIa plaque psoriasis treatment sulfated oxysterol failed to distinguish itself against placebo.
UCB SA said the company’s experimental plaque psoriasis drug bimekizumab produced better results compared to AbbVie Inc.’s blockbuster medicine Humira in reducing the disease’s severity.
Recently published research in the journal Nature Genetics found significant insight into this question: Why does a patient with an autoimmune disease become a type 1 diabetic rather than have rheumatoid arthritis?